Table 5.
Time to first metastasis, univariate analyses
| Variable | Level | N | # with metastases | Hazard Ratio | 95% CI Lower | 95% CI upper | P- Value |
|---|---|---|---|---|---|---|---|
| Univariate analyses | |||||||
| Actin, smooth muscle | >10% pos | 92 | 51 | 0.9286 | 0.1276 | 6.7582 | 0.9417 |
| Caldesmon | >10% pos | 93 | 52 | 0.6418 | 0.288 | 1.4304 | 0.2781 |
| Desmin | >10% pos | 93 | 52 | 0.4643 | 0.2407 | 0.8957 | 0.0221 |
| Myosin, smooth muscle | >10% pos | 91 | 50 | 0.8576 | 0.4156 | 1.7696 | 0.6777 |
| Standard muscle markers | all 4 markers expressed | 90 | 49 | 0.5986 | 0.3255 | 1.101 | 0.0988 |
| ACTG2 | strong, diffuse | 92 | 51 | 1.789 | 0.2462 | 13.0021 | 0.5654 |
| CASQ2 | strong, diffuse | 92 | 51 | 0.6913 | 0.367 | 1.302 | 0.253 |
| CFL2 | strong, diffuse | 87 | 46 | 0.559 | 0.2876 | 1.0868 | 0.0864 |
| MYLK | strong, diffuse | 91 | 50 | 0.9674 | 0.3463 | 2.7026 | 0.9496 |
| SLMAP | strong, diffuse | 93 | 52 | 0.8091 | 0.3794 | 1.7254 | 0.5835 |
| Type-1 leiomyosarcoma markers | muscle enriched (any 3/5) | 90 | 49 | 0.8023 | 0.2872 | 2.2412 | 0.6743 |
| differentiation score | moderate poor |
93 | 52 | 1.104 2.4072 |
0.6043 0.9684 |
2.0171 5.9836 |
0.7476 0.0587 |
| gender (M/F) | M | 93 | 52 | 1.324 | 0.766 | 2.2886 | 0.3148 |
| site (U/S) Size |
Uterine vs all other >5 cm |
93 93 |
52 52 |
0.5359 1.7609 |
0.1927 0.881 |
1.4903 3.5196 |
0.2319 0.1093 |